Q2 EPS Estimates for C4 Therapeutics Decreased by Analyst
C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) – Investment analysts at Brookline Capital Management cut their Q2 2025 earnings per share estimates for C4 Therapeutics in a research note issued on Wednesday, May 7th. Brookline Capital Management analyst L. Cann now expects that the company will earn ($0.43) per share for the quarter, down from […]
C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) – Investment analysts at Brookline Capital Management cut their Q2 2025 earnings per share estimates for C4 Therapeutics in a research note issued on Wednesday, May 7th. Brookline Capital Management analyst L. Cann now expects that the company will earn ($0.43) per share for the quarter, down from […]
